Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

ide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. In March 2007, the FDA granted marketing approval for the Company's first product, Soliris for all patients with PNH and the Company began commercial sale of Soliris in the U.S. during April 2007. In June 2007, the European Commission granted marketing approval for Soliris in the European Union for all patients with PNH. The Company is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is actively pursuing development of other antibody product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: http://www.alexionpharm.com.

This news release contains forward-looking statements, including statements related to potential benefits and commercial potential for Soliris, and interest about Soliris in the patient, physician and payor communities. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to us on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... WOONSOCKET, R.I , April 17, 2015 ... holding a conference call on Friday, May 1, 2015, ... discuss its first quarter financial results. An ... simultaneously through the Investor Relations portion of the CVS ... webcast, visit http://investors.cvshealth.com . This webcast will be ...
(Date:4/17/2015)... April 17, 2015 ASSESS shows ...   is a viable alternative to tumour biopsy   ... all patients with advanced NSCLC   AstraZeneca today ... plasma circulating tumour DNA (ctDNA) testing for epidermal growth factor ... non-small cell lung cancer (NSCLC) in clinical practice. [ ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vrd3bd/mammography ) ... - Global Strategic Business Report" report to their ... for Mammography Equipment in US$ Thousands by the following ... The report provides separate comprehensive analytics for the US, ... , Europe , Asia-Pacific ...
Breaking Medicine Technology:"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4Mammography Equipment (Analog & Digital) Market 2015-2020 - Global Strategic Business Report: Breast Imaging Screening Programs Push Sales 2
... Ill. and NEW YORK, Oct. 6 Physicians ... partner of life sciences companies, today announced a partnership ... OPRX ), to provide healthcare professionals with SampleMD, ... search, select and distribute sample vouchers, prescription co-pay coupons ...
... Yahia Gawad, CEO of CardioGenics Inc. (OTC Bulletin Board: ... month,s Medical Device & Diagnostic Industry Magazine (MD+DI) ... technology. In the article, titled "Improving Diagnosis Times with ... market and the growth of point-of-care testing. ...
Cached Medicine Technology:Physicians Interactive Launches Partnership with SampleMD to Expand Sampling Options for Clinicians and Reduce Costs for Patients 2Physicians Interactive Launches Partnership with SampleMD to Expand Sampling Options for Clinicians and Reduce Costs for Patients 3CardioGenics Featured on Cover of Medical Device & Diagnostic Industry Magazine 2
(Date:4/19/2015)... 19, 2015 HealthPostures, LLC , a ... it will exhibit it’s pioneering ergonomics products at the ... Iowa-Illinois Safety Council Professional Development Conference and Expo . ... EZ are used in volume by call centers, educational ... Built to clamp to a desk, the TaskMate Go ...
(Date:4/18/2015)... Carinsurancesavings.biz has released a new blog post ... during Spring. , Spring can be a great ... make sure they compare the newest policies before deciding ... more about Spring car insurance offers by reading the ... are becoming more and more popular. Many insurance brokerage ...
(Date:4/18/2015)... Insuranceautoquote.info has released a new blog ... quotes . , Clients can review important auto ... online environment provides important advantages for clients who need ... who do not have coverage for their vehicles can ... day or hour. Many agencies offer important discounts and ...
(Date:4/18/2015)... In the past few weeks, TheBeautyPlace.com has been undergoing ... to run maintenance on our shipping facilities to update ... PR Director. "It disrupted our regular shipping schedule but ... on track after having completed the maintenance." , Now, ... which has not allowed some calls to come in ...
(Date:4/18/2015)... PHOENIX, ARIZONA – In March, Mark ... other secure destruction professionals across the United States, earned ... will now display “CSDS” as a professional title with ... National Association of Information Destruction 2015 Annual Conference began ... Of the 20 people who took the exam, Ona ...
Breaking Medicine News(10 mins):Health News:HealthPostures' TaskMate Products to be Exhibited at the Wisconsin and Iowa-Illinois Safety Conferences 2Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:TheBeautyPlace.com Temporary Number Available 2
... instrument for improving patient understanding and acceptance of long-acting injectable antipsychotic ... Psychiatry 2009. 1 This novel, psychosocial approach ... ction planning, I nitiating treatment, and ... discussion tool. , Nonadherence to oral antipsychotic medications is one ...
... Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish nine ... made by the responsible Grants Committee of the DFG ... will initially be funded for four years with a ... the DFG will also provide 20 percent overhead funding ...
... Research Scientists, Engineers and Professionals Slated for Tuesday through Thursday ... ... Boston, MA (PRWEB) May 27, 2009 ... produces online events for the healthcare, education and energy markets, ...
... Ticker Symbol: CURQUEBEC CITY, May 27 /PRNewswire-FirstCall/ - DiagnoCure ... cancer diagnostic tests and delivering laboratory services, announced today ... financial results on June 8, 2009, at approximately 4:30 ... conference call, which will be held on June 9, ...
... Can HelpNORTHRIDGE, Calif., May 27 During these economic ... pocket books. But, putting off important oral health issues ... loss of money. When considering whether it,s time to ... , a true resource for patients wanting to learn ...
... SAN DIEGO, May 27 A growing body of ... of Probiotics" at the American Academy of Physician Assistants ... who attended are an educational bridge to consumers and ... and how to recommend them to their patients. The ...
Cached Medicine News:Health News:New tool to improve patient understanding of long-acting injectable antipsychotic therapies (LAT) unveiled in April issue of Psychiatry 2009 2Health News:DFG establishes nine new collaborative research centers 2Health News:DFG establishes nine new collaborative research centers 3Health News:DFG establishes nine new collaborative research centers 4Health News:DFG establishes nine new collaborative research centers 5Health News:DFG establishes nine new collaborative research centers 6Health News:PlatformQ and LabRoots Announce BioConference Live, Online Conference for the Life Science Research and Laboratory Sciences Community 2Health News:PlatformQ and LabRoots Announce BioConference Live, Online Conference for the Life Science Research and Laboratory Sciences Community 3Health News:DiagnoCure to host Q2 2009 earnings conference call and webcast 2Health News:Oral Health Should Never Be Compromised 2Health News:Interest Surging in Probiotic Foods that Promote Health 2Health News:Interest Surging in Probiotic Foods that Promote Health 3Health News:Interest Surging in Probiotic Foods that Promote Health 4
... System has been developed specifically to fight ... buttocks and hips. It does this by ... excess fluids in your body, which then ... CELLUSSAGE daily, for about 15 minutes each ...
... non-invasive way of shaping your body, ... improving overall skin fitness. ,In its ... rehabilitate scars, burns and damaged muscular ... discovered - the reduction of cellulite ...
... people, you must understand the patients you ... an increasingly aging population, your patients may ... With an incredible 18-inch low height, the ... easy for your practice to accommodate the ...
... is the only treatment of ... topical dermaceutical while exfoliating the ... skin types and addresses a ... including hyperpigmentation, acne, photodamage, dehydration ...
Medicine Products: